Heron Therapeutics, Inc.
$0.32
Market Cap
$59.61M
Shares Outstanding
189.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 27, 1987
Round Lot
100
Locale
US
Day Open
$0.32
Day High
$0.32
Day Low
$0.31
Volume
1.11M
VWAP
$0.32
Prev Close
$0.31
Transactions
--
Acc. Volume
--
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Heron Therapeutics, Inc. (HRTX) closed the 2026-09-16 session at $0.32, up 1.21% versus the previous close (+0.00). The stock opened at $0.32 and traded between $0.31 and $0.32 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $0.32.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Heron Therapeutics, Inc. has a market capitalization of $59.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. HRTX is listed on the XNAS exchange. The company employs approximately 128 people. Heron Therapeutics, Inc. is headquartered in SAN DIEGO, CA. The recorded listing date is 1987-08-27.
On this page you can find market HRTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.